Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
X-linked Charcot-Marie-Tooth disease type 5 (CMTX5) is characterized by early-onset prelingual sensorineural hearing loss, peripheral neuropathy with steppage gait, and optic neuropathy. The causative gene, PRPS1 (HGNC:9462), encodes phosphoribosyl pyrophosphate synthetase 1 (PRS-I), a critical enzyme in purine nucleotide biosynthesis. Affected males typically present in infancy or early childhood with auditory and motor deficits progressing to visual involvement. Female carriers may be asymptomatic or show mild hearing loss due to skewed X-inactivation.
Initial evidence came from two unrelated families (European and Asian descent) harboring the missense mutations c.344T>C (p.Met115Thr) and c.129A>T (p.Glu43Asp) in PRPS1, respectively, with 2 male probands demonstrating sensorineural hearing loss, peripheral neuropathy, and visual loss, and patient erythrocyte assays confirming reduced PRS-I activity ([PMID:17701900]). This X-linked recessive inheritance was supported by co-segregation in multiple affected males across pedigrees.
Subsequent case reports expanded the variant and phenotypic spectrum. A Korean family with a novel hemizygous c.362C>G (p.Ala121Gly) variant in PRPS1 presented with early hearing loss at 5 months, steppage gait by age 6, and peripheral neuropathy but without optic atrophy; segregation in two additional male relatives provided further support ([PMID:24285972]).
Additional hemizygous missense variants have been reported in single CMTX5 patients: c.202A>T (p.Met68Leu) in a French patient with neuropathy, deafness, and optic neuropathy ([PMID:31338985]); c.319A>G (p.Ile107Val) in two siblings with recurrent transient proximal weakness after febrile illness ([PMID:30177296]); and c.82G>C (p.Gly28Arg) in a Japanese patient with typical CMTX5 but milder enzyme deficiency ([PMID:34803094]). No recurrent or founder variants have been described to date.
Functional studies consistently demonstrate a loss-of-function mechanism. Patient-derived enzyme assays show markedly reduced PRS-I activity in erythrocytes and fibroblasts ([PMID:17701896]). A zebrafish prps1a/prps1b double-mutant model recapitulates phenotypes of reduced eye size, decreased hair cell numbers, primary motor neuron defects, and leukopenia, mirroring optic atrophy, hearing impairment, neuropathy, and immunodeficiency seen in human PRPS1-deficient syndromes ([PMID:27425195]).
Overall, the PRPS1–CMTX5 association meets a Strong ClinGen gene–disease validity classification: 7 unrelated male probands, documented X-linked recessive segregation, and concordant functional data. Genetic testing for PRPS1 should be considered in male patients presenting with the triad of early sensorineural hearing loss, peripheral neuropathy, and optic involvement. Identification of PRPS1 mutations enables definitive molecular diagnosis, carrier detection, genetic counseling, and potential exploration of purine replacement therapies.
Gene–Disease AssociationStrong7 unrelated male probands across five families; X-linked recessive segregation; concordant functional enzyme assays and animal model data Genetic EvidenceStrong7 probands (2 families in [PMID:17701900], 1 in [PMID:24285972], 2 in [PMID:30177296], 1 in [PMID:31338985], 1 in [PMID:34803094]); segregation in 2 affected male relatives ([PMID:24285972]) Functional EvidenceModeratePatient enzyme assays show PRS-I loss of function ([PMID:17701896]); zebrafish prps1a/prps1b mutants replicate neuropathy, hearing and optic phenotypes ([PMID:27425195]) |